



Innovative back microsurgery

Press release

VEXIM Launches New Generation SpineJack® Device during SFCR Congress in Paris

- *Improves surgical procedure*
- *Optimizes manufacturing operations*

Toulouse, June 9, 2014 - VEXIM (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces the official launch of the SpineJack® New Generation during the *Société Française de Chirurgie Rachidienne* (SFCR, the French spine surgery society) congress held in Paris from June 5 to 7, 2014.

Backed by its experience with more than 10,000 implants, VEXIM has implemented improvements in its SpineJack® system that have simplified and thereby reduced the surgical stages and improved the fluidity of the procedure for surgeons and radiologists. This more comprehensive and accurate SpineJack® implant kit better meets the requirements of spine surgery experts.

These major improvements have also contributed to optimizing the manufacturing processes, thus positively impacting VEXIM's operating profitability.

Dr. Christian Vasile, orthopedic surgeon at Chambéry hospital, commented: *"This new generation SpineJack® enables us to reduce the operating time in our minimally invasive back interventions, potentially allowing for faster recovery of patients' mobility once their vertebral fractures have been treated."*

Vincent Gardès, CEO of VEXIM, added: *"In launching the new SpineJack® system, we responded quickly to demands from the clinical community and the specific requirements of surgeons. Indeed, this series of major innovations are a direct result of the feedback received from SpineJack® users and will contribute to improving the surgical treatment of Vertebral Compression Fractures."*

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 57 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Chile, Panama and in the following countries where the product is currently being registered: Mexico, Brazil, Venezuela, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3, 2012.

For further information, please go to www.vexim.com

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

SpineJack^{®2}, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Specialized instruments and guided by X-ray allow the implants into the vertebra to be carried out by mini-invasive surgery in approximately 30 minutes enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of three titanium implants with three different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

Contacts

VEXIM
Vincent Gardès
CEO
Jérôme Marzinski
Deputy CEO
Tel: +33 5 61 48 48 38
shareholders@vexim.com

NewCap.
Financial Communications
and Investor Relations
Dusan Oresansky /
Emmanuel Huynh
Tel: +33 1 44 71 94 92
vexim@newcap.fr

Alize RP
Press Relations
Caroline Carmagnol
vexim@alizerp.com
Tel: +33 1 70 22 53 90 /
+33 6 64 18 99 59



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM



² This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.